VivoSeq
Oncology

Human Papilloma Virus

4

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Human Papilloma Virus is an early-stage landscape with 4 programs across 3 companies. The most active players are Eisai, Merck & Co., Xiamen Innovax Biotech Co., Ltd.

Intelligence

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

19/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 2Merck & Co. logo

Merck & Co.

2 programs

Phase 2X

Xiamen Innovax Biotech Co., Ltd

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 80% of 5 pipeline programs.

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Not yet recruiting1 · 20%
Active, not recruiting1 · 20%

Clinical Trials

Trial Activity

A Hybrid Type III Effectiveness - Implementation, Pragmatic Intervention Trial for Cervical Cancer Screen and Treat in Mozambique
Not yet recruiting·TTulane University·Preclinical·NCT06810739·8,445 enrolled
A Pilot Study of Lenvatinib in Combination With Pembrolizumab in HPV-associated Recurrent Respiratory Papillomatosis Patients
Recruiting·YYale University·Phase 2·NCT04645602·20 enrolled
An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Over a Four-year Follow up Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
Active, not recruiting·BBoston Medical Center·Phase 1·NCT05329961·155 enrolled
A Single-center, Randomized, Double-blind, Phase IV Lot-to-lot Consistency Clinical Trial in 18-30 Years-old Females in China to Evaluate Immunogenicity and Safety of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
Recruiting·XXiamen Innovax Biotech Co., Ltd·Approved·NCT07668271·720 enrolled
Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection
Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03351855·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)